Advertisement
Advertisement
March 24, 2026
Abbott’s Esprit BTK System Gains CMS Transitional Pass-Through Payment Status
March 24, 2026—Abbott announced that its transcatheter Esprit below-the-knee (BTK) everolimus-eluting resorbable scaffold system has been approved for transitional pass-through (TPT) payment status by the Centers for Medicare & Medicaid Services (CMS).
According to the announcement on LinkedIn, which was posted by Julie Tyler, Senior Vice President and President of Abbott's Vascular Business, Esprit BTK will now be supported by both the CMS inpatient new technology add-on payment (NTAP) and outpatient TPT reimbursement. The NTAP status became effective in October 2025.
TPT is a 3-year program designed to ensure that Medicare beneficiaries can benefit from innovative technologies without cost becoming a barrier to care. The TPT approval expands access to the Esprit BTK technology, which is designed to restore blood flow, support vessel healing, and protect patients from the most devastating consequences of BTK disease, stated the company.
In April 2024, the company announced FDA approval of the Esprit BTK system for the treatment of patients with BTK chronic limb-threatening ischemia. More information about the device and its reimbursement is available on Abbott’s website. Abbott notes that the TPT is effective April 1, 2026, using code C1743.
Advertisement
Advertisement
